Calixar and VirPath patent granted in the United States

CALIXAR announces the grant of its patent by the United States Patent and Trademark Office for the preparation of vaccine antigens using an innovative splitting approach for the formulation of novel vaccines (US 10144917 B2).

This patent issued from the fruitful collaboration with the academic laboratory VirPath is a great step forward in the generation of safer and more efficient vaccine candidates.

Share on Facebook
Share on Twitter
Share on LinkedIn